A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Four Weeks of Treatment With Imiquimod Creams for Actinic Keratoses.

Trial Profile

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Four Weeks of Treatment With Imiquimod Creams for Actinic Keratoses.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Mar 2014

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Graceway Pharmaceuticals
  • Most Recent Events

    • 28 Jun 2010 Company (Medicis Pharmaceutical Corporation) identified as trial sponsor and as aditional lead centre reported by ClinicalTrials.gov.
    • 26 Mar 2010 According to a Graceway Pharmaceuticals media release, the FDA has approved imiquimod cream 3.75% for the treatment of actinic keratosis lesions based on results from this and other trials in Graceway's phase III programme.
    • 23 Mar 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top